Condition Directory

Breast Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 15, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

678

Shown on this page

Current sort

How Breast Cancer studies are organized in the registry

Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.

Terms that often appear in related listings

triple-negative HER2-positive hormone receptor-positive metastatic breast cancer

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 229–240 of 678 matching trials for Breast Cancer.

Live ClinicalTrials.gov results.

Active filters: "hormone receptor-positive" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: Zelenectide pevedotin (BT8009); Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Breast Cancer
Interventions: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: omega 3 fatty acids; Dietary Supplement
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Duarte, California • Columbus, Ohio

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions: Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 709
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more

Conditions: Breast Neoplasms
Interventions: Imlunestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 137
States / cities: Daphne, Alabama • Huntsville, Alabama • Mobile, Alabama + 115 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Interventions: Best Practice, Biospecimen Collection, Endocrine Drug Therapy, Health Education, Questionnaire Administration, Symptom Specific Assessment Tool; Other · Procedure · Behavioral
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 489
States / cities: Kingman, Arizona • Phoenix, Arizona • Antioch, California + 333 more

Conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
Interventions: INX-315, Fulvestrant, Abemaciclib; Drug
Lead sponsor: Incyclix Bio; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Orlando, Florida • Atlanta, Georgia • Augusta, Georgia + 10 more

Conditions: Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions: Exemestane, Tamoxifen; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions: Samuraciclib, Elacestrant Dihydrochloride; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 2 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

About this Breast Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Breast Cancer clinical trials

How Breast Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

About this Breast Cancer clinical trials directory page